Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000360988

Medchemexpress LLC Protac EZH2 Degrader-1 | 2641601-67-2 | 99.4% | 942.15 | 50 MG
SDP

Catalog No. 5000360988
Encompass_Preferred

PROTAC EZH2 Degrader-1 (Compound 150d) is a potent PROTAC EZH2 Degrader that inhibits EZH2 methyltransferase activity with an IC50 of 2.7 nM. EZH2 is critical in many tumorigenesis and development processes.

  • Potent PROTAC EZH2 Degrader with an IC50 of 2.7 nM for EZH2 methyltransferase activity.
  • Exhibits anti-proliferative activity against various cell lines such as EOL1 (IC50: 3.7 μM), MV4-11 (IC50: 5.5 μM), Pfeiffer (IC50: 0.21 μM), RS4-11 (IC50: 5 μM), and WSUDLCL2 (IC50: 3.69 μM).
  • Inhibits cell viability in H128-LM (IC50: 1.83 nM), H128-BPM (IC50: 1.9 nM), H128 wildtype (IC50: 3.07 nM), and H128-Mut (IC50: 2.64 nM) cells.
  • Enhances the sensitivity of H128-LM cells to Carboplatin, VP16, and VM26.
  • Demonstrates antitumor activity against H128-LM in xenograft mouse models when combined with Carboplatin, VP16, or VM26, prolonging survival.

Catalog No. 50-003-60988 Supplier Medchemexpress LLC Supplier No. HY14752550MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

PROTAC EZH2 Degrader-1 (Compound 150d) is a potent PROTAC EZH2 Degrader that inhibits EZH2 methyltransferase activity with an IC50 of 2.7 nM. EZH2 is critical in many tumorigenesis and development processes.

  • Potent PROTAC EZH2 Degrader with an IC50 of 2.7 nM for EZH2 methyltransferase activity.
  • Exhibits anti-proliferative activity against various cell lines such as EOL1 (IC50: 3.7 μM), MV4-11 (IC50: 5.5 μM), Pfeiffer (IC50: 0.21 μM), RS4-11 (IC50: 5 μM), and WSUDLCL2 (IC50: 3.69 μM).
  • Inhibits cell viability in H128-LM (IC50: 1.83 nM), H128-BPM (IC50: 1.9 nM), H128 wildtype (IC50: 3.07 nM), and H128-Mut (IC50: 2.64 nM) cells.
  • Enhances the sensitivity of H128-LM cells to Carboplatin, VP16, and VM26.
  • Demonstrates antitumor activity against H128-LM in xenograft mouse models when combined with Carboplatin, VP16, or VM26, prolonging survival.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.